Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*

GSK
GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Permitting supply of patented products beyond the agreed licensing territory

GSK
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.
Continue reading
R&D Capacity Building Model

R&D capacity building model

GSK
GSK has a comprehensive model to build local R&D capacity in response to need.
Continue reading

Commitment to R&D for AMR

AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Continue reading
Africa 2020 R&D Capacity Building

Africa 2020 R&D capacity building

GSK
GSK’s Africa 2020 strategy includes a range of R&D capacity building partnerships in sub-Saharan Africa.
Continue reading

Clarity in approach to IP management

AstraZeneca, GSK, Merck KGaA
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Continue reading

Revolving door policy

GSK
GSK has introduced a revolving door policy to mitigate the risk of conflicts of interest for new employees recruited directly from the public sector.
Continue reading
MVacciNation

mVacciNation

GSK
GSK’s mVacciNation programme is a mobile technology-based supply chain management capacity building programme, aiming to increase childhood immunisation in Mozambique.
Continue reading